Ochrobactrum anthropi bacteremia in a child.

Children undergoing chemotherapy for cancer are at increased risk of supervening infection, including bacteremia. This may be due to immunosuppression as well as the presence of intravascular devices such as central venous catheters. Bacteria responsible for these infections include those found in the child\u27s endogenous flora as well as in environmental sources. We report the case of a child with acute lymphoblastic leukemia (ALL) who developed bacteremia secondary to Ochrobactrum anthropi. Details of this extremely rare infection are the focus of this report

Childhood typhoid fever diagnosed in an urban U.S. setting.

The majority of cases of childhood typhoid fever diagnosed in the United States occur in persons recently returned from travel abroad. We report two childhood cases of typhoid fever acquired in Mexico and India and diagnosed in an urban United States setting. This report describes these cases and provides insights into the pitfalls in recognizing this condition in a nonendemic setting as well as information concerning differential diagnosis and treatment

A clustering of childhood meningococcal disease: a challenge for physicians, press and community.

The Delaware Division of Public Health reported only two cases of documented meningococcal infection in the pediatric population in 1992. As of March 1, 1993, the Morbidity and Mortality Weekly Report indicated only one case of meningococcal disease in the state of Delaware for 1993. However, from the end of February to early April 1993, approximately six weeks, there were seven cases of documented meningococcal infection in the pediatric population that either presented or were transferred to one of the pediatric care facilities in the Wilmington, Delaware area. Notification of these cases to the Delaware Division of Public Health prompted the dispersion of a statewide letter concerning the recognition of the clinical signs of meningitis and the proper prophylaxis for meningococcal exposure

Germbuster Brainteaser: A Novel Education Tool

As part of the Pediatric Infectious Diseases elective at the Alfred I. duPont Institute, pediatric residents from the Medical Center of Delaware and the Thomas Jefferson Medical College are encouraged to contribute original, educational material to our Germbusters newsletters. We thought readers of the Delaware Medical Journal would enjoy seeing one of the more innovative resident contributions

Recurrent/persistent pneumonia in a 3 1/2-year-old-girl due to acquired immune deficiency syndrome.

The following is the report of the first case of a Delaware born child who developed AIDS, born from a mother who was not in a high risk camp

Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients

Thirty-five children with symptomatic human immunodeficiency virus infection were enrolled in a 12-week, three-center phase I study of intravenous and oral zidovudine therapy. At enrollment the children ranged in age from 5 months to 13 years, with a median age of 3 1/2 years. Twenty-one children (60%) had acquired immunodeficiency syndrome and 14 (40%) had the related complex; 20 children had <0.5 10 9 CD4+ lymphocytes per liter (<500 cells/mm 3) at entry. Zidovudine was administered in one of three escalating dose regimens. One or two months of intravenous treatment with zidovudine every 6 hours was followed by orally administered drug on the same schedule; zidovudine was infused at 80, 120, or 160 mg/m 2/dose, and the oral dose was one and one-half times the intravenous dosage. Adverse events were similar to those observed in adults. Neutropenia (absolute neutrophil count <0.75 10 9/L (750 cells/mm 3)) occurred in nine patients. The median neutrophil count fell from 2.50 10 9/L at entry to 1.72 10 9/L at the end of the study. Anemia requiring transfusion occurred in seven patients; the median hemoglobin level among nontransfused patients decreased from an entry value of 108 to 105 gm/L (10.8 to 10.5 gm/dl). Dosage adjustments were made in 15 patients, in 12 because of anemia or neutropenia